Is CRISPR Therapeutics a Bargain Buy Amidst Recent Decline?

CRISPR Therapeutics, a gene-editing therapy company, has completed a private offering raising $585.2 million. The company generated $3.5 million in revenue last year and incurred a net loss of $581.6 million. Despite the recent decline in stock price, CRISPR has multiple projects in its pipeline, including CTX211 for Type 1 diabetes, and an approved therapy in Casgevy. The company has a strong financial position with $1.8 billion in working capital.